Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Andrea Grace Bocobo, Renee Wang,Spencer Behr,Julia C. Carnevale,Pelin Cinar,Eric Andrew Collisson,Lawrence Fong,Bridget P. Keenan, Wesley Allen Kidder,Andrew H. Ko,Kanti Pallav Kolli,Megan Kennedy,Angela Laffan, Sorbarikor Piawah,Marin Pollak,Gabriel Schwartz,Julia Whitman,Li Zhang,Katherine Van Loon,Chloe Evelyn Atreya

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 15|浏览4

暂无评分

摘要

77Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects. This study evaluates the safety, tolerability and prelim...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要